Leerink Partnrs Weighs in on Exact Sciences Q2 Earnings

Exact Sciences Co. (NASDAQ:EXAS) – Equities researchers at Leerink Partnrs upped their Q2 2025 earnings per share estimates for shares of Exact Sciences in a research note issued on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $0.03 per share for the quarter, up from their prior forecast of $0.02. The consensus estimate for Exact Sciences’ current full-year earnings is ($1.13) per share.

A number of other brokerages also recently issued reports on EXAS. Piper Sandler reduced their price target on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Craig Hallum reduced their target price on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Raymond James restated a “market perform” rating on shares of Exact Sciences in a research report on Thursday, September 26th. Stifel Nicolaus cut their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group decreased their target price on shares of Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $72.94.

Exact Sciences Stock Performance

Shares of NASDAQ:EXAS opened at $56.68 on Wednesday. Exact Sciences has a 12-month low of $40.62 and a 12-month high of $79.62. The company’s 50 day moving average price is $58.09 and its two-hundred day moving average price is $58.56. The firm has a market cap of $10.49 billion, a PE ratio of -48.44 and a beta of 1.24. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The business had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. The business’s revenue was up 12.8% compared to the same quarter last year.

Hedge Funds Weigh In On Exact Sciences

Hedge funds have recently modified their holdings of the business. William Blair Investment Management LLC bought a new position in Exact Sciences during the 2nd quarter worth $163,896,000. Groupama Asset Managment acquired a new stake in shares of Exact Sciences in the third quarter valued at about $821,000. Sculptor Capital LP bought a new position in shares of Exact Sciences during the second quarter worth about $32,819,000. Samlyn Capital LLC acquired a new position in shares of Exact Sciences in the second quarter worth approximately $30,426,000. Finally, Armistice Capital LLC boosted its holdings in Exact Sciences by 91.6% in the second quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company’s stock valued at $59,154,000 after acquiring an additional 669,438 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Insiders Place Their Bets

In other Exact Sciences news, CEO Kevin T. Conroy purchased 19,500 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was purchased at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the transaction, the chief executive officer now owns 1,074,191 shares in the company, valued at $55,159,707.85. The trade was a 1.85 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.36% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.